Antipsychotic choice: understanding shared decision-making among doctors and patients

References

• Australian Health Ministers Advisory Council. (2013). A national framework for recovery-oriented mental health services: Guide for practitioners and providers. Canberra: Commonwealth of Australia.
   Google Scholar
• Barnes, T. R. E., Shingleton-Smith, A., & Paton, C. (2009). Antipsychotic long-acting injections: Prescribing practice in the UK. British Journal of Psychiatry, 195(S52), s37–s42. doi:10.1192/bjp.195.52.s37
   Google Scholar
• Bech, M., Kjaer, T., & Lauridsen, J. (2011). Does the number of choice sets matter? Results from a web survey applying a discrete choice experiment. Health Economics, 20(3), 273–286. doi:10.1002/hec.1587
   PubMed Web of Science ®Google Scholar
• Bosanac, P., & Castle, D. J. (2015). Why are long-acting injectable antipsychotics still underused? BJPsych Advances, 21(2), 98–105. doi:10.1192/apt.bp.114.013565
   Google Scholar
• Bridges, J. F., Kinter, E. T., Schmeding, A., Rudolph, I., & Mühlbacher, A. (2011). Can Patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks? The Patient, 4(4), 267–275. doi:10.2165/11589190-000000000-00000
   PubMedGoogle Scholar
• Bridges, J. F., Slawik, L., Schmeding, A., Reimer, J., Naber, D., & Kuhnigk, O. (2013). A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expectations, 16(2), 164–176. doi:10.1111/j.1369-7625.2011.00704.x
   PubMed Web of Science ®Google Scholar
• Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014). The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal. Therapeutic Advances in Psychopharmacology, 4(5), 198–219. doi:10.1177/2045125314540297
   PubMedGoogle Scholar
• Carlsson, F., & Martinsson, P. (2003). Design techniques for stated preference methods in health economics. Health Economics, 12(4), 281–294. doi:10.1002/hec.729
   PubMed Web of Science ®Google Scholar
• Caroli, F., Raymondet, P., Izard, I., Plas, J., Gall, B., & Delgado, A. (2011). Opinions of French patients with schizophrenia regarding injectable medication. Patient Preference and Adherence, 5, 165–171. doi:10.2147/PPA.S15337
   PubMed Web of Science ®Google Scholar
• Castle, D., Copolov, D., Wykes, T., & Mueser, K. (2012). Pharmacological and psychosocial treatments in schizophrenia (3rd ed.). London: CRC Press.
   Google Scholar
• Castle, D., Keks, N., Newton, R., Schweitzer, I., Copolov, D., Paoletti, N., … Tiller, J. (2013). Pharmacological approaches to the management of schizophrenia: 10 years on. Australasian Psychiatry, 21(4), 329–334. doi:10.1177/1039856213486211
   PubMed Web of Science ®Google Scholar
• ChoiceMetrics, N. (2012). 1.1.1 User manual & reference guide. Australia: ChoiceMetrics.
   Google Scholar
• Chopra, P., Hamilton, B., Castle, D., Smith, J., Mileshkin, C., Deans, M., … Wilson, M. (2009). Implementation of the strengths model at an area mental health service. Australasian Psychiatry, 17(3), 202–206. doi:10.1080/10398560802666083
   PubMed Web of Science ®Google Scholar
• Coulter, A., & Collins, A. (2011). Making shared decision-making a reality: No decision about me, without me. London: The Kings Fund.
   Google Scholar
• De Las Cuevas, C., Peñate, W., Perestelo-Pérez, L., & Serrano-Aguilar, P. (2013). Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9). Neuropsychiatric Disease and Treatment, 9, 1045–1052. doi:10.2147/NDT.S49021
   PubMed Web of Science ®Google Scholar
• Drake, R. E., Cimpean, D., & Torrey, W. C. (2009). Shared decision making in mental health: Prospects for personalized medicine. Dialogues in Clinical Neuroscience, 11(4), 455–463.
   PubMedGoogle Scholar
• Edlinger, M., Hofer, A., Rettenbacher, M. A., Baumgartner, S., Widschwendter, C. G., Kemmler, G., … Fleischhacker, W. W. (2009). Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophrenia Research, 113(2–3), 246–251. doi:10.1016/j.schres.2009.06.008
   PubMed Web of Science ®Google Scholar
• Fujikawa, M., Togo, T., Yoshimi, A., Fujita, J., Nomoto, M., Kamijo, A., … Hirayasu, Y. (2008). Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(3), 755–760. doi:10.1016/j.pnpbp.2007.12.002
   PubMed Web of Science ®Google Scholar
• Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., … Tran, N. (2016). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry, 50(5), 410–472. doi:10.1177/0004867416641195
   PubMed Web of Science ®Google Scholar
• Geerts, P., Martinez, G., & Schreiner, A. (2013). Attitudes towards the administration of long-acting antipsychotics: A survey of physicians and nurses. BMC Psychiatry, 13, 58. doi:10.1186/1471-244X-13-58
   PubMed Web of Science ®Google Scholar
• Ghanouni, A., Halligan, S., Taylor, S. A., Boone, D., Plumb, A., Stoffel, S., … von Wagner, C. (2014). Quantifying public preferences for different bowel preparation options prior to screening CT colonography: A discrete choice experiment. BMJ Open, 4(4), e004327. doi:10.1136/bmjopen-2013-004327
   PubMed Web of Science ®Google Scholar
• Hamann, J., Cohen, R., Leucht, S., Busch, R., & Kissling, W. (2005). Do patients with schizophrenia wish to be involved in decisions about their medical treatment? American Journal of Psychiatry, 162(12), 2382–2384. doi:10.1176/appi.ajp.162.12.2382
   PubMed Web of Science ®Google Scholar
• Hamann, J., Kruse, J., Schmitz, F., Kissling, W., & Pajonk, F. (2010). Patient participation in antipsychotic drug choice decisions. Psychiatry Research, 178(1), 63–67. doi:10.1016/j.psychres.2008.08.008
   PubMed Web of Science ®Google Scholar
• Heres, S., Schmitz, F. S., Leucht, S., & Pajonk, F. G. (2007). The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology, 22(5), 275–282. doi:10.1097/YIC.0b013e3280c28424
   PubMed Web of Science ®Google Scholar
• Higashi, K., Medic, G., Littlewood, K., Diez, T., Granström, O., & De Hert, M. (2013). Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology, 3(4), 200–218. doi:10.1177/2045125312474019
   PubMedGoogle Scholar
• Kaplan, S., Greenfield, S., Gandek, B., Rogers, W., & Ware, J. (1996). Characteristics of physicians with participatory decision-making styles. Annals of Internal Medicine, 124(5), 497. doi:10.7326/0003-4819-124-5-199603010-00007
   PubMed Web of Science ®Google Scholar
• Katz, E. G., Hauber, B., Gopal, S., Fairchild, A., Pugh, A., Weinstein, R. B., & Levitan, B. S. (2016). Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence, 10, 2127–2139.
   PubMed Web of Science ®Google Scholar
• Kenicer, D., Ellahi, R., Davies, P., Walker, A., & Cheyne, A. (2016). Factors important to psychiatrists when prescribing depot antipsychotics. Progress in Neurology and Psychiatry, 20(3), 16–20. doi:10.1002/pnp.428
   Web of Science ®Google Scholar
• Kessels, R. (2003). Patients' memory for medical information. Journal of the Royal Society of Medicine, 96(5), 219–222. doi:10.1258/jrsm.96.5.219
   PubMed Web of Science ®Google Scholar
• Lally, J., & MacCabe, J. (2015). Antipsychotic medication in schizophrenia: A review. British Medical Bulletin, 114(1), 169–179. doi:10.1093/bmb/ldv017
   PubMed Web of Science ®Google Scholar
• Lancsar, E., & Louviere, J. (2008). Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics, 26(8), 661–677. doi:10.2165/00019053-200826080-00004
   PubMed Web of Science ®Google Scholar
• Levitan, B., Markowitz, M., Mohamed, A. F., Johnson, F. R., Alphs, L., Citrome, L., & Bridges, J. F. (2015). Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatric Services, 66(7), 719–726. doi:10.1176/appi.ps.201400188
   PubMed Web of Science ®Google Scholar
• Markowitz, M. A., Levitan, B. S., Mohamed, A. F., Johnson, F. R., Bridges, J. F., Alphs, L., & Citrome, L. (2014). Psychiatrists’ judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatric Services, 65(9), 1133–1139. doi:10.1176/appi.ps.201300290
   PubMed Web of Science ®Google Scholar
• Matthias, M., Salyers, M., Rollins, A., & Frankel, R. (2012). Decision making in recovery-oriented mental health care. Psychiatric Rehabilitation Journal, 35(4), 305–314. doi:10.2975/35.4.2012.305.314
   PubMed Web of Science ®Google Scholar
• Montgomery, A. A., & Fahey, T. (2001). How do patients’ treatment preferences compare with those of clinicians? Quality in Health Care, 10(Supplement 1), i39–i43. doi:10.1136/qhc.0100039.
   PubMedGoogle Scholar
• Morant, N., Kaminskiy, E., & Ramon, S. (2016). Shared decision making for psychiatric medication management: Beyond the micro-social. Health Expectations, 19(5), 1002–1014. doi:10.1111/hex.12392
   PubMed Web of Science ®Google Scholar
• Patel, M. X., & David, A. S. (2005). Why aren’t depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment, 11(3), 203–213. doi:10.1192/apt.11.3.203
   Google Scholar
• Potkin, S., Bera, R., Zubek, D., & Lau, G. (2013). Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry, 13, 261. doi:10.1186/1471-244X-13-261
   PubMed Web of Science ®Google Scholar
• Reed Johnson, F., Lancsar, E., Marshall, D., Kilambi, V., Mühlbacher, A., Regier, D. A., … Bridges, J. F. P. (2013). Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(1), 3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Ryan, M., & Gerard, K. (2003). Using discrete choice experiments to value health care programmes: Current practice and future research reflections. Applied Health Economics and Health Policy, 2(1), 55–64.
   PubMedGoogle Scholar
• Swait, J., & Louviere, J. (1993). The role of the scale parameter in the estimation and comparison of multinomial logit-models. Journal of Marketing Research, 30(3), 305–314. doi:10.2307/3172883
   Web of Science ®Google Scholar
• Valenstein, M., Copeland, L. A., Owen, R., Blow, F. C., & Visnic, S. (2001). Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. The Journal of Clinical Psychiatry, 62(7), 545–551. doi:10.4088/JCP.v62n07a08
   PubMed Web of Science ®Google Scholar
• Waddell, L., & Taylor, M. (2008). A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. Journal of Psychopharmacology (Oxford, England), 22(3), 238–243. doi:10.1177/0269881107087976
   PubMed Web of Science ®Google Scholar